Profile data is unavailable for this security.
About the company
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
- Revenue in USD (TTM)0.00
- Net income in USD-259.34m
- Incorporated2018
- Employees207.00
- LocationImmunovant Inc320 West 37Th StreetNEW YORK 10018United StatesUSA
- Phone+1 (917) 580-3099
- Fax+1 (302) 636-5454
- Websitehttps://immunovant.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Corcept Therapeutics Incorporated | 523.53m | 118.02m | 3.02bn | 352.00 | 27.10 | 5.50 | 25.34 | 5.76 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Arrowhead Pharmaceuticals Inc | 35.47m | -470.79m | 3.21bn | 525.00 | -- | 6.63 | -- | 90.47 | -4.24 | -4.24 | 0.3189 | 3.90 | 0.0384 | -- | -- | 67,567.62 | -51.72 | -20.02 | -57.39 | -24.65 | -- | -- | -1,346.13 | -61.79 | -- | -80.00 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
Ultragenyx Pharmaceutical Inc | 442.59m | -613.35m | 3.25bn | 1.28k | -- | 23.13 | -- | 7.33 | -8.02 | -8.02 | 5.75 | 1.69 | 0.329 | 1.61 | 6.18 | 346,854.20 | -45.59 | -33.35 | -55.09 | -38.30 | 88.59 | 93.13 | -138.58 | -154.71 | 2.28 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
Dyne Therapeutics Inc | 0.00 | -257.40m | 3.28bn | 143.00 | -- | 6.02 | -- | -- | -3.97 | -3.97 | 0.00 | 5.49 | 0.00 | -- | -- | 0.00 | -63.48 | -52.81 | -67.12 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
Axsome Therapeutics Inc | 251.02m | -296.38m | 3.50bn | 545.00 | -- | 24.26 | -- | 13.93 | -6.38 | -6.38 | 5.41 | 3.03 | 0.537 | 2.11 | 3.43 | 460,592.70 | -63.40 | -64.55 | -85.88 | -82.23 | 90.12 | -- | -118.07 | -227.05 | 3.09 | -55.54 | 0.556 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
Crinetics Pharmaceuticals Inc | 1.97m | -235.46m | 3.57bn | 290.00 | -- | 4.07 | -- | 1,810.89 | -3.77 | -3.77 | 0.0315 | 11.14 | 0.0031 | -- | 0.3653 | 6,806.90 | -35.57 | -42.53 | -37.86 | -45.36 | -- | -- | -11,641.13 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
Neogen Corp | 929.24m | 1.57m | 3.68bn | 2.64k | 2,359.22 | 1.17 | 31.26 | 3.97 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.37 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
Guardant Health Inc | 603.73m | -460.90m | 3.70bn | 1.78k | -- | 53.88 | -- | 6.12 | -3.92 | -3.92 | 5.17 | 0.5607 | 0.3754 | 4.37 | 7.03 | 339,362.00 | -28.66 | -22.26 | -33.02 | -24.59 | 60.37 | 64.62 | -76.34 | -97.07 | 5.66 | -59.55 | 0.9435 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
Avidity Biosciences Inc | 10.87m | -228.68m | 3.79bn | 253.00 | -- | 4.56 | -- | 348.76 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Immunovant Inc | 0.00 | -259.34m | 3.80bn | 207.00 | -- | 6.13 | -- | -- | -1.89 | -1.89 | 0.00 | 4.24 | 0.00 | -- | -- | 0.00 | -48.37 | -- | -52.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
Immunitybio Inc | 302.00k | -600.96m | 4.12bn | 628.00 | -- | -- | -- | 13,648.16 | -1.05 | -1.05 | 0.0005 | -1.02 | 0.0008 | -- | 0.1677 | 480.89 | -161.65 | -112.76 | -946.50 | -316.07 | -- | -- | -199,138.70 | -37,700.74 | -- | -1.93 | 5.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
Alkermes Plc | 1.73bn | 599.95m | 4.15bn | 2.10k | 7.00 | 3.30 | 6.24 | 2.40 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Alvotech SA | 114.39m | -494.28m | 4.25bn | 999.00 | -- | -- | -- | 37.18 | -2.05 | -2.05 | 0.4909 | -2.47 | 0.117 | 1.69 | 1.97 | 114,507.50 | -50.54 | -- | -63.82 | -- | -23.89 | -- | -432.09 | -- | 0.8107 | -1.26 | 2.49 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.66m | 5.24% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 6.32m | 4.33% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.96m | 2.71% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.64m | 2.49% |
Perceptive Advisors LLCas of 31 Mar 2024 | 2.96m | 2.03% |
Armistice Capital LLCas of 31 Mar 2024 | 2.16m | 1.48% |
Alpine Global Management LLCas of 31 Mar 2024 | 1.88m | 1.29% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.82m | 1.25% |
Viking Global Investors LPas of 31 Mar 2024 | 1.81m | 1.24% |
Logos Global Management LPas of 31 Mar 2024 | 1.78m | 1.22% |